{"url_path":"/sec/nvct/8-k/2026-06-30/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-079360-index.html","accession_number":"0001104659-26-079360","cik":"0001875558","ticker":"NVCT","issuer_name":"Nuvectis Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-079360-index.html","primary_entity_key":"0001875558","primary_entity_name":"Nuvectis Pharma, Inc."},"word_count":280,"has_tables":true,"body_markdown":"false\n0001875558\n\n0001875558\n\n2026-06-29\n2026-06-29\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n** **\n\n**FORM 8-K**\n\n** **\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the**\n\n**Securities Exchange Act of 1934**\n\n \n\nDate of report (Date of earliest event reported):\n**June 29, 2026**\n\n \n\n**Nuvectis Pharma, Inc.**\n\n(Exact Name of Registrant as Specified in Charter)\n\n \n\n**Delaware**\n\n(State or Other Jurisdiction\n\nof Incorporation)\n \n**001-41264**\n\n(Commission File Number)\n \n**86-2405608**\n\n(IRS Employer Identification No.)\n\n \n\n**1 Bridge Plaza Suite 275**\n\n**Fort Lee, NJ 07024**\n\n(Address of Principal Executive Offices)\n\n \n\n**(201) 614-3150**\n\n(Registrant’s telephone number, including\narea code)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act.\n\n \n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act.\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class:**\n**Trading Symbol(s)**\n**Name of each exchange on which registered:**\n\nCommon Stock\nNVCT\nNasdaq Capital Market\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company x\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ¨"}